Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 4 of 4 entries
View as:

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05205109 Org: User:
Start: 06/07/22 End: 02/28/28 Due: 02/28/29

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03591965 Org: User:
Start: 08/07/18 End: 08/03/22 Due: 08/03/23

A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04281420 Org: User:
Start: 04/13/20 End: 10/02/23 Due: 10/02/24

Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04305249 Org: User:
Start: 08/15/20 End: 05/24/24 Due: 05/24/25